PMC:7025468 / 5786-6717 JSONTXT

{"project":"TEST0","denotations":[{"id":"32117283-149-155-3683892","span":{"begin":276,"end":278},"obj":"[\"20668216\"]"}],"text":"Reagents, Treatment of Cells\nFor methamphetamine (Meth) treatment, cells were plated at an initial density of 2 × 106cells/mL. Meth was administered once per day at a final concentration of 100 μM, consistent with observed concentrations of Meth in samples from Meth abusers (35). For cultures with HIV-1, cells were pretreated with Meth for 24 h, followed by infection with HIV-1. Cells treated with IL-1RA were given 200 or 400 ng/mL IL-1RA as described (Shenandoah Biotechnology Inc., Warwick, PA), followed by treatment with 100 μM Meth 2 h later if applicable. Cells treated with both HIV-1 and IL-1RA were pretreated for 24 h with IL-1RA before becoming infected with HIV-1. Cells treated with IFNα2 were administered 100U/mL IFNα2 (PBL Assay Science, Piscataway, NJ) for 2 h prior to treatment with 100 μM Meth. Cells treated with both HIV-1 and IFNα2 were pretreated for 24 h with IFNα2 before becoming infected with HIV-1."}

{"project":"2_test","denotations":[{"id":"32117283-20668216-35221698","span":{"begin":276,"end":278},"obj":"20668216"}],"text":"Reagents, Treatment of Cells\nFor methamphetamine (Meth) treatment, cells were plated at an initial density of 2 × 106cells/mL. Meth was administered once per day at a final concentration of 100 μM, consistent with observed concentrations of Meth in samples from Meth abusers (35). For cultures with HIV-1, cells were pretreated with Meth for 24 h, followed by infection with HIV-1. Cells treated with IL-1RA were given 200 or 400 ng/mL IL-1RA as described (Shenandoah Biotechnology Inc., Warwick, PA), followed by treatment with 100 μM Meth 2 h later if applicable. Cells treated with both HIV-1 and IL-1RA were pretreated for 24 h with IL-1RA before becoming infected with HIV-1. Cells treated with IFNα2 were administered 100U/mL IFNα2 (PBL Assay Science, Piscataway, NJ) for 2 h prior to treatment with 100 μM Meth. Cells treated with both HIV-1 and IFNα2 were pretreated for 24 h with IFNα2 before becoming infected with HIV-1."}

{"project":"MyTest","denotations":[{"id":"32117283-20668216-35221698","span":{"begin":276,"end":278},"obj":"20668216"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Reagents, Treatment of Cells\nFor methamphetamine (Meth) treatment, cells were plated at an initial density of 2 × 106cells/mL. Meth was administered once per day at a final concentration of 100 μM, consistent with observed concentrations of Meth in samples from Meth abusers (35). For cultures with HIV-1, cells were pretreated with Meth for 24 h, followed by infection with HIV-1. Cells treated with IL-1RA were given 200 or 400 ng/mL IL-1RA as described (Shenandoah Biotechnology Inc., Warwick, PA), followed by treatment with 100 μM Meth 2 h later if applicable. Cells treated with both HIV-1 and IL-1RA were pretreated for 24 h with IL-1RA before becoming infected with HIV-1. Cells treated with IFNα2 were administered 100U/mL IFNα2 (PBL Assay Science, Piscataway, NJ) for 2 h prior to treatment with 100 μM Meth. Cells treated with both HIV-1 and IFNα2 were pretreated for 24 h with IFNα2 before becoming infected with HIV-1."}